ArticleWorld journal of gastrointestinal surgery2025
Fluid therapy strategies in acute pancreatitis: Randomized controlled trial comparing dextran and Ringer's lactate.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis (AP) is a frequent gastrointestinal emergency characterized by inflammation. It has the potential to progress to organ failure. Fluid therapy plays a critical role in early AP management, mitigating hypovolemia-induced ischemia and systemic inflammatory response syndrome (SIRS).
aimTo evaluate dextran 40 + Ringer's lactate solution (RLS)
methodsWe conducted a single-center, single-blind, randomized controlled trial involving 108 patients with mild to moderate AP. Participants were randomized to receive either dextran 40 + RLS (1:3 ratio) or RLS alone. All patients underwent standardized, goal-directed fluid therapy and were monitored for clinical response, inflammatory markers, and complications. The primary outcomes were reduction in C-reactive protein (CRP) and resolution of SIRS at 72 hours. Secondary outcomes included organ failure, intensive care unit admission, mortality, and length of hospital stay.
resultsThe dextran 40 + RLS group demonstrated significantly lower CRP levels. No differences were observed in SIRS changes, fluid overload, refractory status mortality, local complications, or organ failure rates. Hospitalization tended to be shorter in the dextran 40 + RLS group (5 days
conclusionDextran 40 + RLS improved the early CRP response in patients with AP without added complications. Although medium-term outcomes were similar, early benefits support its use in initial management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.